8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Apr 17, 2026·SEC
Emergent BioSolutions Inc.(EBS)Earnings, Financials & Key Ratios
EBS•NYSE
$9.14
$472M mkt cap·9.8× P/E·Price updated May 7, 2026
AboutEmergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Show more
- Revenue$743M-28.8%
- EBITDA$209M+6825.8%
- Net Income$53M+127.6%
- EPS (Diluted)0.93+125.8%
- Gross Margin47.19%+31.2%
- EBITDA Margin28.07%+9549.7%
- Operating Margin14.83%+242.4%
- Net Margin7.08%+138.8%
- ROE10.46%+131.1%
- ROIC8.48%+227.8%
- Debt/Equity1.09-21.8%
- Interest Coverage1.86+352.8%
EBS Key Insights
Emergent BioSolutions Inc. (EBS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 21.1% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Profits declining 29.7% over 5 years
- ✗Sales declining 14.0% over 5 years
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
EBS Price & Volume
Emergent BioSolutions Inc. (EBS) stock price & volume — 10-year historical chart
Loading chart...
EBS Growth Metrics
Emergent BioSolutions Inc. (EBS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.26%
5 Years-13.98%
3 Years-12.72%
TTM-28.81%
Profit CAGR
10 Years-1.77%
5 Years-29.68%
3 Years-
TTM127.6%
EPS CAGR
10 Years-4.08%
5 Years-30.34%
3 Years-
TTM122.46%
Return on Capital
10 Years1.5%
5 Years-8.15%
3 Years-15.55%
Last Year9.13%
EBS Recent Earnings
Emergent BioSolutions Inc. (EBS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 7/12 qtrs (64%)
Q2 2026Latest
Apr 30, 2026EPS
$0.21
Est $0.25
+184.0%
Revenue
$156M
Est $145M
+7.7%
Q1 2026
Feb 26, 2026EPS
$0.43
Est $0.11
-490.9%
Revenue
$149M
Est $218M
-31.6%
Q4 2025
Oct 29, 2025EPS
$1.06
Est $0.12
+983.3%
Revenue
$231M
Est $218M
+6.3%
Q3 2025
Aug 6, 2025EPS
$0.16
Est $0.26
+161.5%
Revenue
$141M
Est $204M
-30.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.21vs $0.25+184.0% | $156Mvs $145M+7.7% |
| Q1 2026 | Feb 26, 2026 | $0.43vs $0.11-490.9% | $149Mvs $218M-31.6% |
| Q4 2025 | Oct 29, 2025 | $1.06vs $0.12+983.3% | $231Mvs $218M+6.3% |
| Q3 2025 | Aug 6, 2025 | $0.16vs $0.26+161.5% | $141Mvs $204M-30.8% |
Based on last 12 quarters of dataView full earnings history →
EBS Peer Comparison
Emergent BioSolutions Inc. (EBS) competitors in Vaccines and biodefense products — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SIGA | 338.88M | 4.73 | 14.33 | -31.8% | -43117.39% | -10.67% | 0.00 | |
 PRGO | 1.61B | 11.72 | -1.14 | -2.75% | -43.5% | -50.65% | 1.35 | |
 BRKR | 6.66B | 43.73 | -291.53 | 2.08% | -0.34% | -0.5% | 0.81 | |
 ABCL | 1.45B | 4.82 | -9.84 | 160.56% | -194.89% | -15.14% | 0.14 | |
 PCRX | 929.88M | 23.64 | 147.75 | 3.63% | 1.27% | 1.31% | 0.66 | |
 PFE | 150.63B | 26.48 | 19.47 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 277.34B | 112.29 | 15.42 | 1.18% | 28.12% | 36.14% | 0.96 | |
 JNJ | 536.23B | 222.51 | 38.43 | 4.3% | 27.26% | 31.69% | 0.51 |
Compare EBS vs Peers
Emergent BioSolutions Inc. (EBS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EBS Income Statement
Emergent BioSolutions Inc. (EBS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 560.9M | 782.4M | 1.11B | 1.58B | 1.77B | 1.12B | 1.05B | 1.04B | 742.9M |
| Revenue Growth % | 14.75% | 39.49% | 41.36% | 42.61% | 12.45% | -36.99% | -6.1% | -0.54% | -28.81% |
| Cost of Goods Sold | 277.3M | 462M | 622.9M | 714.2M | 980.4M | 644.5M | 689.3M | 668.2M | 392.3M |
| COGS % of Revenue | 49.44% | 59.05% | 56.32% | 45.28% | 55.28% | 57.67% | 65.69% | 64.03% | 52.81% |
| Gross Profit | 283.6M▲ 0% | 320.4M▲ 13.0% | 483.1M▲ 50.8% | 863.1M▲ 78.7% | 793.2M▼ 8.1% | 473M▼ 40.4% | 360M▼ 23.9% | 375.4M▲ 4.3% | 350.6M▼ 6.6% |
| Gross Margin % | 50.56% | 40.95% | 43.68% | 54.72% | 44.72% | 42.33% | 34.31% | 35.97% | 47.19% |
| Gross Profit Growth % | 15.85% | 12.98% | 50.78% | 78.66% | -8.1% | -40.37% | -23.89% | 4.28% | -6.61% |
| Operating Expenses | 159.3M | 230.6M | 369M | 424.6M | 451.8M | 643M | 1.09B | 484.1M | 240.4M |
| OpEx % of Revenue | 28.4% | 29.47% | 33.36% | 26.92% | 25.47% | 57.54% | 103.54% | 46.39% | 32.36% |
| Selling, General & Admin | 142.9M | 202.5M | 273.5M | 304.1M | 348.7M | 339.5M | 356.7M | 298.7M | 186.6M |
| SG&A % of Revenue | 25.48% | 25.88% | 24.73% | 19.28% | 19.66% | 30.38% | 33.99% | 28.62% | 25.12% |
| Research & Development | 97.4M | 142.8M | 226.2M | 237.9M | 235.2M | 188.3M | 111.4M | 70.7M | 53.8M |
| R&D % of Revenue | 17.36% | 18.25% | 20.45% | 15.08% | 13.26% | 16.85% | 10.62% | 6.77% | 7.24% |
| Other Operating Expenses | -81M | -114.7M | -130.7M | -117.4M | -132.1M | 115.2M | 618.3M | 114.7M | 0 |
| Operating Income | 124.3M▲ 0% | 89.8M▼ 27.8% | 114.1M▲ 27.1% | 438.5M▲ 284.3% | 341.4M▼ 22.1% | -170M▼ 149.8% | -726.4M▼ 327.3% | -108.7M▲ 85.0% | 110.2M▲ 201.4% |
| Operating Margin % | 22.16% | 11.48% | 10.32% | 27.8% | 19.25% | -15.21% | -69.23% | -10.42% | 14.83% |
| Operating Income Growth % | 17.82% | -27.76% | 27.06% | 284.31% | -22.14% | -149.79% | -327.29% | 85.04% | 201.38% |
| EBITDA | 166.9M | 152M | 222.1M | 548.5M | 459.6M | -45M | -605.3M | -3.1M | 208.5M |
| EBITDA Margin % | 29.76% | 19.43% | 20.08% | 34.77% | 25.91% | -4.03% | -57.69% | -0.3% | 28.07% |
| EBITDA Growth % | 16.14% | -8.93% | 46.12% | 146.96% | -16.21% | -109.79% | -1245.11% | 99.49% | 6825.81% |
| D&A (Non-Cash Add-back) | 42.6M | 62.2M | 108M | 110M | 118.2M | 125M | 121.1M | 105.6M | 98.3M |
| EBIT | 132.1M | 92.9M | 150.9M | 499.2M | 386M | -109.3M | -168.1M | -52.2M | 110.2M |
| Net Interest Income | -6.6M | -9.9M | -38.4M | -31.3M | -34.5M | -37.3M | -87.9M | -71M | -59.3M |
| Interest Income | 1.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 6.59M | 9.9M | 38.4M | 31.3M | 34.5M | 37.3M | 87.9M | 71M | 59.3M |
| Other Income/Expense | -5.7M | -8.3M | -36.7M | -26.6M | -38.2M | -49M | -4.8M | -34.2M | -27.4M |
| Pretax Income | 118.6M▲ 0% | 81.5M▼ 31.3% | 77.4M▼ 5.0% | 411.9M▲ 432.2% | 303.2M▼ 26.4% | -219M▼ 172.2% | -731.2M▼ 233.9% | -142.9M▲ 80.5% | 82.8M▲ 157.9% |
| Pretax Margin % | 21.14% | 10.42% | 7% | 26.11% | 17.1% | -19.6% | -69.68% | -13.69% | 11.15% |
| Income Tax | 36M | 18.8M | 22.9M | 106.1M | 83.7M | -7.4M | 29.3M | 47.7M | 30.2M |
| Effective Tax Rate % | 30.35% | 23.07% | 29.59% | 25.76% | 27.61% | 3.38% | -4.01% | -33.38% | 36.47% |
| Net Income | 82.6M▲ 0% | 62.7M▼ 24.1% | 54.5M▼ 13.1% | 305.8M▲ 461.1% | 219.5M▼ 28.2% | -211.6M▼ 196.4% | -760.5M▼ 259.4% | -190.6M▲ 74.9% | 52.6M▲ 127.6% |
| Net Margin % | 14.73% | 8.01% | 4.93% | 19.39% | 12.38% | -18.94% | -72.48% | -18.26% | 7.08% |
| Net Income Growth % | 59.46% | -24.09% | -13.08% | 461.1% | -28.22% | -196.4% | -259.4% | 74.94% | 127.6% |
| Net Income (Continuing) | 82.6M | 62.7M | 54.5M | 305.8M | 219.5M | -211.6M | -760.5M | -190.6M | 52.6M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.71▲ 0% | 1.22▼ 28.7% | 1.04▼ 14.8% | 5.67▲ 445.2% | 4.06▼ 28.4% | -4.22▼ 203.9% | -14.85▼ 251.9% | -3.60▲ 75.8% | 0.93▲ 125.8% |
| EPS Growth % | 51.33% | -28.66% | -14.75% | 445.19% | -28.4% | -203.94% | -251.9% | 75.76% | 125.83% |
| EPS (Basic) | 1.98 | 1.25 | 1.06 | 5.79 | 4.10 | -4.22 | -14.85 | -3.60 | 0.98 |
| Diluted Shares Outstanding | 50.33M | 51.4M | 52.4M | 53.8M | 54.1M | 50.1M | 51.2M | 53M | 56.7M |
| Basic Shares Outstanding | 41.82M | 50.1M | 51.5M | 52.7M | 53.5M | 50.1M | 51.2M | 53M | 53.5M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
EBS Balance Sheet
Emergent BioSolutions Inc. (EBS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 485.39M | 620.8M | 686.2M | 1.2B | 1.27B | 1.21B | 679.5M | 598.7M | 662.5M |
| Cash & Short-Term Investments | 178.29M | 112.2M | 168M | 621.3M | 576.3M | 642.6M | 111.7M | 99.5M | 205.4M |
| Cash Only | 178.29M | 112.2M | 168M | 621.3M | 576.3M | 642.6M | 111.7M | 99.5M | 205.4M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 146.1M | 262.5M | 275.3M | 230.9M | 278.9M | 159.2M | 191M | 154.5M | 84.2M |
| Days Sales Outstanding | 95.07 | 122.46 | 90.85 | 53.43 | 57.4 | 52 | 66.44 | 54.04 | 41.37 |
| Inventory | 142.81M | 205.8M | 222.5M | 307M | 344.5M | 350.7M | 328.9M | 311.7M | 343.4M |
| Days Inventory Outstanding | 187.98 | 162.59 | 130.38 | 156.9 | 128.26 | 198.61 | 174.16 | 170.26 | 319.5 |
| Other Current Assets | 1M | 200K | 20.4M | 2.2M | 70.2M | 57.9M | 47.9M | 33M | 29.5M |
| Total Non-Current Assets | 584.82M | 1.61B | 1.64B | 1.69B | 1.69B | 1.96B | 1.14B | 791M | 656.1M |
| Property, Plant & Equipment | 407.21M | 510.2M | 567M | 675.1M | 828.4M | 837M | 399M | 270.6M | 205.4M |
| Fixed Asset Turnover | 1.38x | 1.53x | 1.95x | 2.34x | 2.14x | 1.34x | 2.63x | 3.86x | 3.62x |
| Goodwill | 49.13M | 259.7M | 266.6M | 266.7M | 224.9M | 218.2M | 0 | 0 | 0 |
| Intangible Assets | 119.6M | 811.6M | 741.9M | 663.1M | 604.6M | 728.8M | 566.6M | 501.5M | 436.5M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 6.05M | 13.7M | 52.2M | 82.4M | 29.9M | 171.9M | 178.1M | 18.9M | 14.2M |
| Total Assets | 1.07B▲ 0% | 2.23B▲ 108.3% | 2.33B▲ 4.4% | 2.88B▲ 23.9% | 2.96B▲ 2.6% | 3.17B▲ 7.1% | 1.82B▼ 42.4% | 1.39B▼ 23.8% | 1.32B▼ 5.1% |
| Asset Turnover | 0.52x | 0.35x | 0.48x | 0.55x | 0.60x | 0.35x | 0.58x | 0.75x | 0.56x |
| Asset Growth % | 10.32% | 108.32% | 4.39% | 23.89% | 2.58% | 7.05% | -42.42% | -23.78% | -5.12% |
| Total Current Liabilities | 100.07M | 200.4M | 216.3M | 384.5M | 374M | 1.23B | 651.3M | 162.4M | 132.2M |
| Accounts Payable | 41.8M | 80.7M | 94.8M | 136.1M | 128.9M | 103.5M | 112.2M | 60.9M | 55.6M |
| Days Payables Outstanding | 55.02 | 63.76 | 55.55 | 69.56 | 47.99 | 58.62 | 59.41 | 33.27 | 51.73 |
| Short-Term Debt | 0 | 10.1M | 16.4M | 39.5M | 37.4M | 963.1M | 413.7M | 2.7M | 0 |
| Deferred Revenue (Current) | 13.23M | 10.6M | 0 | 0 | 11.7M | 26.4M | 0 | 0 | 0 |
| Other Current Liabilities | 7.2M | 36.3M | 42.7M | 72M | 107.3M | 48.6M | 106.8M | 81.1M | 76.6M |
| Current Ratio | 4.85x | 3.10x | 3.17x | 3.11x | 3.40x | 0.98x | 1.04x | 3.69x | 5.01x |
| Quick Ratio | 3.42x | 2.07x | 2.14x | 2.31x | 2.47x | 0.70x | 0.54x | 1.77x | 2.41x |
| Cash Conversion Cycle | 228.03 | 221.29 | 165.68 | 140.77 | 137.66 | 192 | 181.19 | 191.03 | 309.14 |
| Total Non-Current Liabilities | 57.79M | 1.02B | 1.02B | 1.05B | 972.2M | 549.7M | 522.6M | 744.5M | 663.8M |
| Long-Term Debt | 13.5M | 784.5M | 798.4M | 850.3M | 809.4M | 448.5M | 446.5M | 663.7M | 572.1M |
| Capital Lease Obligations | 0 | 0 | 22.1M | 27.8M | 24.2M | 14.8M | 0 | 9.7M | 0 |
| Deferred Tax Liabilities | 12.5M | 67.5M | 63.9M | 0 | 93.3M | 59.7M | 0 | 41.7M | 37.8M |
| Other Non-Current Liabilities | 44.3M | 103.6M | 52.5M | 173.6M | 40.6M | 26.7M | 76.1M | 29.4M | 53.9M |
| Total Liabilities | 157.86M | 1.22B | 1.24B | 1.44B | 1.35B | 1.78B | 1.17B | 906.9M | 796M |
| Total Debt | 13.46M | 794.6M | 836.9M | 923M | 871M | 1.43B | 860.2M | 676.1M | 572.1M |
| Net Debt | -164.84M | 682.4M | 668.9M | 301.7M | 294.7M | 783.8M | 748.5M | 576.6M | 366.7M |
| Debt / Equity | 0.01x | 0.79x | 0.77x | 0.64x | 0.54x | 1.03x | 1.32x | 1.40x | 1.09x |
| Debt / EBITDA | 0.08x | 5.23x | 3.77x | 1.68x | 1.90x | - | - | - | 2.74x |
| Net Debt / EBITDA | -0.99x | 4.49x | 3.01x | 0.55x | 0.64x | - | - | - | 1.76x |
| Interest Coverage | 20.05x | 9.38x | 3.93x | 15.95x | 11.19x | -2.93x | -1.91x | -0.74x | 1.86x |
| Total Equity | 912.35M▲ 0% | 1.01B▲ 10.8% | 1.09B▲ 7.7% | 1.45B▲ 32.9% | 1.61B▲ 11.4% | 1.39B▼ 13.9% | 649.3M▼ 53.2% | 482.8M▼ 25.6% | 522.6M▲ 8.2% |
| Equity Growth % | 53.03% | 10.8% | 7.68% | 32.94% | 11.37% | -13.89% | -53.21% | -25.64% | 8.24% |
| Book Value per Share | 18.13 | 19.67 | 20.77 | 26.90 | 29.79 | 27.70 | 12.68 | 9.11 | 9.22 |
| Total Shareholders' Equity | 912.35M | 1.01B | 1.09B | 1.45B | 1.61B | 1.39B | 649.3M | 482.8M | 522.6M |
| Common Stock | 50K | 100K | 100K | 100K | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 337.07M | 367.3M | 421.8M | 726.9M | 950.3M | 738.7M | -21.8M | -212.4M | -159.8M |
| Treasury Stock | -39.5M | -39.6M | -39.6M | -39.6M | -152.2M | -227.7M | -227.7M | -227.7M | 0 |
| Accumulated OCI | -3.7M | -5.5M | -9.9M | -25.3M | -16.1M | 3.1M | -5.7M | -5.2M | -7.5M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBS Cash Flow Statement
Emergent BioSolutions Inc. (EBS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 208.14M | 41.8M | 188M | 536.9M | 321.1M | -34.1M | -206.3M | 58.7M | 170.6M |
| Operating CF Margin % | 37.11% | 5.34% | 17% | 34.04% | 18.1% | -3.05% | -19.66% | 5.62% | 22.96% |
| Operating CF Growth % | 289.14% | -79.92% | 349.76% | 185.59% | -40.19% | -110.62% | -504.99% | 128.45% | 190.63% |
| Net Income | 82.59M | 62.7M | 54.5M | 305.8M | 230.9M | -211.6M | -760.5M | -190.6M | 52.6M |
| Depreciation & Amortization | 42.57M | 62.2M | 110.7M | 114.5M | 123.8M | 143.3M | 125.1M | 108.8M | 95.8M |
| Stock-Based Compensation | 15.21M | 23.2M | 26.7M | 51.8M | 42.4M | 45.1M | 23.1M | 18M | 16.2M |
| Deferred Taxes | 3.26M | 8.6M | -1.1M | -3.3M | 46.9M | -28.6M | -8.9M | -5.5M | -4M |
| Other Non-Cash Items | 10.78M | 4.2M | 39.6M | 58.6M | 33.5M | 19.8M | 485.2M | 39.3M | 32.4M |
| Working Capital Changes | 53.72M | -119.1M | -42.4M | 9.5M | -156.4M | -2.1M | -70.3M | 88.7M | -22.4M |
| Change in Receivables | -4.81M | -94.2M | -8.2M | 27.5M | -48.2M | 118.1M | -21.6M | -24.4M | 25.5M |
| Change in Inventory | 6.07M | -1.9M | -16.7M | -66.9M | -44M | -57.1M | 600K | -24.5M | -30.3M |
| Change in Payables | 16.13M | -7M | 16.5M | 28.3M | -2.5M | -14M | 10.6M | -33M | -8.4M |
| Cash from Investing | -249.93M | -897.2M | -96.9M | -151.9M | -225M | -381.3M | 212.3M | 125.2M | 69.4M |
| Capital Expenditures | -54.83M | -72.1M | -86.9M | -141.9M | -225M | -115.8M | -51.6M | -22.9M | -13.8M |
| CapEx % of Revenue | 9.78% | 9.22% | 7.86% | 9% | 12.69% | 10.36% | 4.92% | 2.19% | 1.86% |
| Acquisitions | -195.1M | -827.7M | 0 | 0 | 0 | 0 | 270.2M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -195.1M | 2.6M | -10M | -10M | 0 | -265.5M | -6.3M | 148.1M | 83.2M |
| Cash from Financing | -51.4M | 788.7M | -35.9M | 69.5M | -141M | 481.2M | -535.7M | -190M | -136.6M |
| Debt Issued (Net) | -20M | 795.2M | 13.7M | 62.9M | -35.9M | 564.2M | -543.4M | -198.4M | -112.5M |
| Equity Issued (Net) | -13.8M | -100K | 0 | 0 | -106M | -82.1M | 8.4M | 9.3M | -22.7M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -33.1M | -100K | 0 | 0 | -106M | -82.1M | 0 | 0 | -24.9M |
| Other Financing | -17.6M | -6.4M | -49.6M | 6.6M | 900K | -900K | -700K | -900K | -1.4M |
| Net Change in Cash | -93.22M▲ 0% | -66.9M▲ 28.2% | 55.6M▲ 183.1% | 453.5M▲ 715.6% | -45.2M▼ 110.0% | 66.3M▲ 246.7% | -530.9M▼ 900.8% | -6.1M▲ 98.9% | 103.5M▲ 1796.7% |
| Free Cash Flow | 153.31M▲ 0% | -30.3M▼ 119.8% | 101.1M▲ 433.7% | 395M▲ 290.7% | 96.1M▼ 75.7% | -149.9M▼ 256.0% | -257.9M▼ 72.0% | 35.8M▲ 113.9% | 156.8M▲ 338.0% |
| FCF Margin % | 27.33% | -3.87% | 9.14% | 25.04% | 5.42% | -13.41% | -24.58% | 3.43% | 21.11% |
| FCF Growth % | 773.3% | -119.76% | 433.66% | 290.7% | -75.67% | -255.98% | -72.05% | 113.88% | 337.99% |
| FCF per Share | 3.05 | -0.59 | 1.93 | 7.34 | 1.78 | -2.99 | -5.04 | 0.68 | 2.77 |
| FCF Conversion (FCF/Net Income) | 2.52x | 0.67x | 3.45x | 1.76x | 1.46x | 0.16x | 0.27x | -0.31x | 3.24x |
| Interest Paid | 8.4M | 10.2M | 34.5M | 21M | 30.4M | 33M | 68.3M | 64M | 0 |
| Taxes Paid | 12M | 14M | 30.8M | 109.3M | 71.6M | 6.2M | 52.8M | 26.5M | 0 |
EBS Key Ratios
Emergent BioSolutions Inc. (EBS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 8.25% | 10.95% | 6.52% | 5.19% | 24.12% | 14.35% | -14.11% | -74.67% | -33.67% | 10.46% |
| Return on Invested Capital (ROIC) | 13.26% | 13.91% | 5.52% | 4.96% | 18.76% | 14.01% | -6.25% | -30.53% | -6.64% | 8.48% |
| Gross Margin | 50.08% | 50.56% | 40.95% | 43.68% | 54.72% | 44.72% | 42.33% | 34.31% | 35.97% | 47.19% |
| Net Margin | 10.6% | 14.73% | 8.01% | 4.93% | 19.39% | 12.38% | -18.94% | -72.48% | -18.26% | 7.08% |
| Debt / Equity | 0.45x | 0.01x | 0.79x | 0.77x | 0.64x | 0.54x | 1.03x | 1.32x | 1.40x | 1.09x |
| Interest Coverage | 12.43x | 20.05x | 9.38x | 3.93x | 15.95x | 11.19x | -2.93x | -1.91x | -0.74x | 1.86x |
| FCF Conversion | 1.03x | 2.52x | 0.67x | 3.45x | 1.76x | 1.46x | 0.16x | 0.27x | -0.31x | 3.24x |
| Revenue Growth | -0.11% | 14.75% | 39.49% | 41.36% | 42.61% | 12.45% | -36.99% | -6.1% | -0.54% | -28.81% |
EBS SEC Filings & Documents
Emergent BioSolutions Inc. (EBS) SEC filings — annual & quarterly reports (10-K, 10-Q)
EBS Frequently Asked Questions
Emergent BioSolutions Inc. (EBS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Emergent BioSolutions Inc. (EBS) reported $742.9M in revenue for fiscal year 2025. This represents a 1540% increase from $45.3M in 2001.
Emergent BioSolutions Inc. (EBS) saw revenue decline by 28.8% over the past year.
Yes, Emergent BioSolutions Inc. (EBS) is profitable, generating $52.6M in net income for fiscal year 2025 (7.1% net margin).
Dividend & Returns
Emergent BioSolutions Inc. (EBS) has a return on equity (ROE) of 10.5%. This is reasonable for most industries.
Emergent BioSolutions Inc. (EBS) generated $156.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More EBS
Emergent BioSolutions Inc. (EBS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates